TITLE

QLT GETS POSITIVE OPINIONS FOR QLT091001 AS ORPHAN DRUG

PUB. DATE
March 2011
SOURCE
Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article provides information on the oral synthetic retinoid, QLT091001, a drug developed by QLT Inc. in Vancouver, British Columbia, for the treatment of two diseases of inherited blindness which include the leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). It reports that the drug has received good reviews from the European Medicines Agency (EMA) and Committee for Orphan Medicinal Products (COMP), as a potential treatment for RP and LCA. More details about RP, LCA, Synthetic Retinoid Drugs and the developer QLT, are provided.
ACCESSION #
58691937

 

Related Articles

  • INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;10/25/2011, Vol. 29 Issue 20, p62 

    This section offers news briefs related to the ophthalmic industry as of October 2011. A teaching module on staging codes has been issued by the American Glaucoma Society. It cites a share purchase agreement between pharmaceutical firms Santen Pharmaceutical and Novagali Pharma in which the...

  • Gene therapy successfully treats blindness. Sheth, Parul R. // Current Science (00113891);7/10/2008, Vol. 95 Issue 1, p17 

    The article presents a study bringing the foundation for gene therapy approaches to the treatment of Leber's congenital amaurosis (LCA) and other forms of retinal degeneration. The study sponsored by the Centre for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia,...

  • A Case Report of Vogt's Limbal Girdle and Retinitis Pigmentosa in a Thirteen-Year-Old Boy: A Rare and Unusual Association. Vignesh, A.P.; Srinivasan, Renuka; Karanth, Swathi; Vijitha, Sai // Case Reports in Ophthalmology;Sep-Dec2015, Vol. 6 Issue 3, p311 

    Aim: To describe a rare case of Vogt's limbal girdle in a boy with retinitis pigmentosa. Methods: A 13-year-old boy from India presented to us with progressive diminution of vision and nyctalopia for 5 years. On examination, he had the characteristic features of retinitis pigmentosa with the...

  • We've Got the Gene, so Where Is the Cure? Marmorstein, Alan // Review of Ophthalmology;Oct2000, Vol. 7 Issue 10, p68 

    Focuses on the limitation of gene treatment for Stargardt disease or retinitis pigmentosa. Identification of genes causing eye diseases; Availability of therapies in the form of lifestyle and dietary changes; Cost of drug discovery process; Importance of knowledge on the localization and...

  • Screening of patients with retinitis pigmentosa for heredopathia atactica polyneuritiformis (Refsum's disease).  // British Medical Journal (Clinical Research Edition);4/13/1985, Vol. 290 Issue 6475, p1109 

    Investigates the association between retinitis pigmentosa and heredopathia atactica polyneuritiformis, also known as Refsum's disease in Great Britain. Manifestation of the characteristics of the condition; Presentation of case report of patients retinitis pigmentosa; Importance of screening of...

  • Synthesis of the Nakanishi Ring-Locked Retinoid. Côté, Jamie B.; Quach, Tan D.; Demenev, Andrey P.; Garvey, David S.; Berman, Judd M. // International Journal of Medicinal Chemistry;2011, p1 

    An optimized synthetic route to prepare ring-locked retinoid 1a has been developed. We fully describe a purification protocol that provides isomerically pure 1a in support of on-going proof of concept studies for the development of therapeutic agents to treat human ADRP. Additionally, we have...

  • QLT: Combo AMD Therapy Cuts Retreatments.  // Review of Ophthalmology;Jul2010, Vol. 17 Issue 7, p7 

    The article offers information on the release of the 24-month results of QLT Inc.'s Phase II Radical study in patients with age-related macular degeneration (AMD). It notes that the study intends to compare the retreatment rates of Visudyne combined with Lucentis and Lucentis monotherapy while...

  • In This Issue.  // Molecular Therapy;May2009, Vol. 17 Issue 5, p754 

    The article discusses various topics published within the issue including one on the antioxidant therapy for retinitis pigmentosa, another on the multicomponent, systemic siRNA delivery system and another on the use of a clustered integrin-binding platform.

  • Treatment of retinitis pigmentosa.  // British Medical Journal;6/5/1976, Vol. 1 Issue 6022, p1358 

    Examines the treatment for retinitis pigmentosa. Description of retinitis pigmentosa as a heterogenous group of heritable disorders; Prognosis of the disease; Influence of retinitis pigmentosa on hereditary blindness.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics